98: 52 Week High: CA$2. 87%. 5 million as of December 31, 2022. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial. NervGen Pharma Corp. As of Nov 01. The net cash burn for Q2 2022 from operating activities was approximately $3. Bill Radvak is a co-founder and has been the Executive Chairman or Chairman of NervGen since its inception. 3915 +0. - NervGen Pharma Corp. 1. Forecast Changes; Commodities. The corporate office of the Company is located at 2955 Virtual Way, Suite 480, Vancouver, BC, V5M 4X6, Canada, and the registered office is located at Suite 2600,Vancouver, British Columbia--(Newsfile Corp. (NGENF) stocks, the next step is researching the company. (TSX-V: NGEN;. The company’s lead target. 13% Year to date 10. 3% and is now trading at $1. 88, which is an increase of 127. NGENF shares are trading down $0. 14. Vancouver, Canada. 5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury NervGen Pharma Corp. Since then, NGENF stock has increased by 19. 01 (. Track NervGen Pharma Corp (NGENF) Stock Price, Quote, latest community messages, chart, news and other stock related information. NervGen Pharma Corp. 65%) Gold 1,969. NOT FOR DISTRIBUTION TO U. Read more. Vancouver, British Columbia--(Newsfile Corp. forecasts only using an unbiased methodology and our. F Stock Report. 13. These lofty numbers are. 33, which is within the analyst’s predicted range. 0 million as of March 31, 2021, compared to $5. Read More ». (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has engaged. See the latest NervGen Pharma Corp Ordinary Shares stock price (XTSX:NGEN), related news, valuation, dividends and more to help you make your investing decisions. Currently, those suffering from a spinal cord injury. Stock Price & Overview 433 followers $1. 02:06:08 2021-04-01 pm EDT 5-day change 1st Jan Change. . 0 million as of March 31, 2023. 10. - April 10, 2023) - NervGen Pharma Corp. June 27, 2023. m. Vancouver, British Columbia-- (Newsfile Corp. For instance, just consider the fact that Wall Street analysts are now estimating peak annual sales for Biogen’s new drug will range from $10 billion to $50 billion. - October 23, 2023) - NervGen Pharma Corp. CA64082X2032. NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. An investor that had 100 shares of stock prior to the reverse split would have 13 shares. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal. 5 million as of December 31, 2022. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. Vancouver, Canada. Ruffolo exercisable at a price of $1. All options. 68NervGen Pharma Completes Dosing in its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results. What this means: InvestorsObserver gives Nervgen Pharma Corp (NGENF) an overall rank of 32, which is below average. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI),. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease in which the immune system attacks myelin (the fatty coating around neurons) in the brain and spinal cord, damaging the neurons and impairing signal transmission. -1. ( CVE:NGEN ) by taking the. As of 2023 November 11, Saturday current price of NGENF stock is 1. is a clinical-stage biotech company. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. NervGen (TSXV: NGEN) (OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and. This was offset by approximately $0. 00. The latest NervGen Pharma stock prices, stock quotes, news, and NGENF. 62% over the past 2 weeks. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 Oct 27 NervGen Pharma Corp. Today’s Change. Dr Silver’s innovation offers renewed hope for the estimated 300,000 to 500,00 North Americans who dream of one-day regaining sensation and motor function in their paralysed limbs. Currency in CAD. 0 million as of March 31, 2023. 3 Bil: BMRN Biomarin Pharmaceutical Inc: Jdmlf: $15. Company Overview; 1 Valuation;. 23: NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management will be presenting at two upcoming. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. Michael Kelly to the. Receives Up to $1. +3. Research NervGen Pharma's (TSXV:NGEN) stock key valuation metrics while comparing it with its industry peers & market side by side. NervGen Pharma Corp. NervGen Pharma's estimated fair value is CA$3. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021. 1. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares at a. +1. NervGen Pharma Corp. , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided an update on its Phase 1 program with NVG-291 at the Society for Neuroscience’s Neuroscience. Alnylam Pharmaceuticals Inc: Kkvsytx: $20. Stock After deciding where to buy NervGen Pharma Corp. These lofty numbers are. Stock-based compensation - - 633,953 - 633,953 Loss and comprehensive loss - - - (3,021,547) (3,021,547). Discover NervGen Pharma's earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. NervGen's lead drug candidate, NVG-291, is currently planned to be evaluated in a Phase 1b/2a clinical trial. 06/27/2023 - 08:30 AM . June 27, 2023. Vorticom, Inc. NervGen Pharma Corp. 05 today. - September 11, 2023) - NervGen Pharma Corp. NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates. The company’s lead target. NOT FOR DISTRIBUTION TO U. Vancouver, Canada October 18, 2021 – NervGen Pharma Corp. Cash and investments of $18. S. NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. 2 based on 2 Stage Free Cash Flow to Equity. Stable Share Price: NGEN is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week. Kelly has also been appointed as amember of NervGen's Board of Directors. 07. (NGENF) stock price, news, historical charts, analyst ratings and financial information from WSJ. Complete NervGen Pharma Corp. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. For NervGen Pharma, we've compiled three additional factors you should further research: Risks : Be aware that NervGen Pharma is showing 5 warning signs in our investment analysis , and 3 of those. , through its subsidiary, NervGen US Inc. On July 13, 2022, we closed a non-brokered private placement of 10,150,000 units of the Company at a price of US$1. View the latest NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing. forecasts only using an unbiased methodology and our. ,. 10% most volatile stocks in CA Market. About NervGen. Vancouver, Canada. 50(-0. July 27, 2020 — NervGen Pharma Corp. 5 million as of December 31, 2022. 3 million in proceeds from the exercise of options and warrants during the. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury. (the "Company" or "NervGen") and should be read in conjunction with the accompanying consolidated financial statements and related notes thereto for the year ended December 31, 2021. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and. The company’s lead target. The company's initial target indications are spinal cord injury, Alzheimer's disease and multiple sclerosis. Stock-based compensation - - 775,997 - 775,997 Loss and comprehensive loss - - - (2,247,417) (2,247,417). 8 million as of September 30, 2023, compared to $22. 0164 / +1. 08. Valneva has brought its vaccine against Chikungunya fever to market maturity. Vancouver, British Columbia-- (Newsfile Corp. , a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will host a 1-hour panel. NervGen Pharma Corp. - February 28, 2022) - NervGen Pharma Corp. com 604. Vancouver, Canada. Share your opinion and gain insight from other stock traders and investors. 19%) Crude Oil 76. com. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative. Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024. Vancouver, British Columbia--(Newsfile Corp. Dr. C. 1. - June 20, 2023) - NervGen Pharma Corp. 0 Bil: INCYView live NervGen Pharma Corp. - October 25, 2022) - NervGen Pharma Corp. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. 03%)Discover NervGen Pharma's earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. NervGen Pharma Corp. 42. CI. NervGen Pharma Corp. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 376,000 incentive stock options to. 2m. (TSX-V: NGEN;. The options have been granted in accordance with the policies of the. is a private company incorporated on January 19, 2017 as 1104403 B. 0 million. 12,500. Loading more data. NervGen Pharma Corp. Vancouver, Canada. Radvak has been the chief executive officer and director of multiple start-up companies. NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system. NervGen Pharma is a buy, says Paradigm. All resolutions submitted for approval were passed by shareholders Vancouver, Canada, May 18, 2023 — NervGen Pharma Corp. - August 8, 2023) - NervGen Pharma Corp. . Vancouver, Canada--(Newsfile Corp. NervGen's lead drug candidate, NVG-291, is currently planned for a Phase 1b/2a clinical trial. 97 NGEN 0. VANCOUVER, British Columbia--(BUSINESS WIRE)-- NervGen Pharma Corp. The stock just got a big boost from new clinical results, and that bodes well for fans of NervGen Pharma (NervGen Pharma Stock Quote, Charts, News, Analysts, Financials TSXV:NGEN), according to iA. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial of the Company's proprietary lead compound, NVG-291, have completed dosing. NervGen Pharma Corp. Vancouver, British Columbia–(Newsfile Corp. ,. com - August 22 at 9:08 AM. NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an. Vancouver, British Columbia--(Newsfile Corp. 52%) At close: 03:59PM EST 1d 5d 1m 6m YTD 1y 5y Max Full. 63% 6 months 11. Russell 2000 Futures 1,736. Vancouver - NervGen Pharma Corp. NervGen Pharma Corp (OTCQX International:NGENF) 1. NervGen Pharma has already demonstrated in animals that its drug can heal nerve damage. - November 27, 2019) - NervGen Pharma Corp. U. August 9, 2023 at 8:30 AM · 10 min read. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of John Ruffolo. NervGen Pharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the second quarter ended June 30, 2023. What this means: InvestorsObserver gives Nervgen Pharma Corp (NGENF) an overall rank of 32, which is below average. NervGen Pharma Corp. 1. 32; its P/E ratio is -5. 3915 +0. 0 million as of March 31, 2023 Vancouver, Canada. Unlock for free. News Ideas Financials Technicals Forecast . NervGen Pharma Corp. closed the transaction. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General. September 5, 2023 – NervGen Pharma Corp. According to present data NervGen Pharma's NGENF shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). 19 at the beginning of 2023. The net cash burn for Q2 2023 from operating activities was approximately $2. +0. During the 2022 fiscal year and 2023 to date, we have received proceeds of approximately CA$3. (TSX-V: NGEN) (OTCQX: NGENF). NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. NervGen Pharma Corp (OTCQX International:NGENF) 1. S. Kelly exercisable at a price of $1. NGENF shares are trading down $0. 'NervGen made. May 15, 2023 – NervGen Pharma Corp. June 20, 2023 – NervGen Pharma Corp. 92% from the latest price. (TSX-V: NGEN) (OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be giving an oral presentation at the upcoming American Spinal Injury Association (ASIA) 50th Annual. The following discussion is management's assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. May 12, 2022 – NervGen Pharma Corp. Vancouver - NervGen Pharma Corp. - February 28, 2022) - NervGen Pharma Corp. 50 per unit, for aggregate gross proceeds of. (the “Company” or “NervGen”) is a publicly traded company incorporated on January 19, 2017 under the Business Corporations Act (British Columbia). NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates. Vancouver, British Columbia--(Newsfile Corp. NOT FOR DISTRIBUTION TO U. Vancouver, British Columbia-- (Newsfile Corp. (NGEN. September 12, 2022 – NervGen Pharma Corp. Today −2. February 24, 2020 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“ NervGen ” the “ Company ”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has priced its previously announced offering of equity securities (the. View live NERVGEN PHARMA CORP chart to track its stock's price action. C. July 14, 2022— NervGen Pharma Corp. This step is necessary to understand whether this company fits your financial goals and strategy. The stock at $80 million mkt cap can 10 to 100 bag as. 7200. According to present data NervGen Pharma's NGEN shares and potentially its market environment have been in bearish cycle last 12 months (if exists). NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada November 4, 2021 – NervGen Pharma Corp. About NervGen. 65 per. 5 million as of December 31, 2022As at September 30, 2023, we have achieved three of the five milestones in the grant, and received US$1. February 14, 2023 […] Cash and Investments: NervGen had cash and investments of $14. NervGen Pharma Stock Forecast, NGEN stock price prediction. V) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments The NervGen Pharma Corp. NervGen Pharma Corp. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. 5 million for the same period in 2021. NervGen Pharma has raised a total of. View the latest NervGen Pharma Corp. - April 10, 2023) - NervGen Pharma Corp. NervGen Pharma Corp. 5 million as of December 31, 2022. 75 per share for a period of five years and that vest equally every three months over a one-year period. Restoring Life's Potential by Creating Innovative Solutions for the Treatment of Nervous System Damage | NervGen is a publicly traded (TSX-V. - May 15, 2023) - NervGen Pharma Corp. Jerry Silver, inventor of. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. - September 5, 2023) - NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 225,000 incentive stock options to Directors,. NervGen had cash and investments of $14. 94(+4. com Corporate Communications Huitt Tracey(604) 537-2094 Media Inquiries Vorticom, Inc. (NGEN. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. finance. Receives Up to $1. , there are approximately 913,000 people living with MS 1 Rates of MS. Stock analysis for NervGen Pharma Corp (NGENF:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 3564. Forecast Changes; Commodities. Stroke Onward: Bringing Awareness and. finance. holds the exclusive worldwide rights to NVG-291, and the drug is also currently being tested in a Phase 1 clinical trial in healthy human subjects. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen had cash and investments of $14. The corporate office of the Company is located atNervGen Pharma Corp. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. Vancouver, British Columbia--(Newsfile Corp. 00 per share. The following discussion is management's assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. The net. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. 9800 +0. Vancouver, British Columbia--(Newsfile Corp. - November 8, 2023) - NervGen Pharma Corp. 1. July 22, 2020 — NervGen Pharma Corp. Nervgen Pharma Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Equity proceeds of CA$22M+ raised during 2022 fiscal year; Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoingNervGen Pharma Corp. Vancouver, British Columbia-- (Newsfile Corp. Paul Brennan to. 950 CAD. Vancouver, Canada. Jerry Silver, inventor of NervGen's. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury. Receives Up to $1. (the "Company" or "NervGen") and should be read in conjunction with the accompanying consolidated financial statements and related notes thereto for the period ended September 30, 2021. The net cash burn for Q1 2021 from operating. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NGENF | Complete NervGen Pharma Corp. The net cash burn for Q1 2021 from operating. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and. Wall Street Stock Market & Finance report, prediction for the future: You'll find the NervGen Pharma share forecasts, stock quote and buy / sell signals below. announced the formation of its Multiple Sclerosis Clinical Advisory Board comprised of six world-class scientific and clinical researchers in the field of multiple sclerosis:. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the first quarter ended March 31, 2023. For more information. NervGen Pharma announces that it has received fast track designation from the FDA for NVG-291, a novel drug that aims to restore nerve function after spinal cord injury. (TSX-V: NGEN) (OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date of certain stock options granted to a consultant of the. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " the " Company "), a biotech company dedicated to creating innovative. stock news by MarketWatch. Vancouver, Canada. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. NervGen Pharma Corp. - February 23, 2023) - NervGen Pharma Corp. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. 3. 35 (1. June 27, 2023 – NervGen Pharma Corp. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation granted by U. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. 2955 Virtual WaySuite 480Vancouver, BC V5M 4X6 Phone: (778) 731-1711Email: info@nervgen.